PainChek Expands US Footprint with Eldermark Partnership, Stock Soars on Growth Prospects

Key Highlights:

• PainChek (ASX: PCK) partners with Eldermark to enter US long-term care market.
• Stock up 16.67% to $0.056, marking a 52-week high.
• FDA De Novo clearance awaited to unlock full US market access.
  
   

PainChek Limited (ASX: PCK) surged over 16% on Monday to $0.056—a 52-week high—as the company announced a pivotal partnership with Eldermark Software, a leading US-based care management system provider. The collaboration positions PainChek for a transformative entry into the vast US long-term care market, pending FDA De Novo clearance for its Adult App.

PainChek’s breakthrough technology—an AI-powered, smartphone-based pain assessment tool—has already demonstrated strong traction across Australia, the UK, and Europe, where it holds regulatory clearance. The Eldermark agreement, effective immediately and renewable annually, empowers Eldermark to offer PainChek’s solution to over 116,000 clients in its network, covering senior living facilities across the US and Canada.

“This agreement with Eldermark is a key milestone as we expand our presence in the US market in anticipation of FDA clearance,” said PainChek CEO Philip Daffas. “Together, we aim to deliver best-practice pain management and improve quality of life for residents.”

The integration of PainChek into Eldermark’s existing care management platform is expected to enhance care outcomes by providing real-time, AI-assisted pain assessments, reducing caregiver burden, and supporting regulatory compliance. The financial impact of the deal remains unquantified, but market sentiment has been overwhelmingly positive, as reflected in today’s stock surge.

PainChek’s technology addresses a significant gap in pain management—especially for those unable to self-report pain, such as people living with dementia or communication impairments. Globally, the company has completed over 10 million digital pain assessments and has partnerships with 1,800 aged care facilities.

The US market represents a major growth frontier for PainChek. The need for advanced pain assessment tools in the US long-term care sector is critical, given an aging population and increasing focus on value-based care. The Eldermark partnership effectively positions PainChek as a frontrunner in this space, while FDA approval remains the key catalyst for unlocking full commercial potential.

With a market cap now exceeding $103 million and a year-to-date return of 84%, PainChek’s momentum is building. Investors will be closely watching for FDA clearance in the coming months, which could mark the next major inflection point for the company.